Market Overview

UPDATE: Canaccord Genuity Raises HeartWare International's PT

Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking

According to a research report published this morning, Canaccord Genuity has increased HeartWare International's (NASDAQ: HTWR) PT from $95 to $101.

In the report, Canaccord Genuity commented, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."

Canaccord Genuity maintains its Buy rating on HeartWare International, which closed yesterday at $77.14.

Latest Ratings for HTWR

May 2015JP MorganMaintainsOverweight
May 2015BarclaysMaintainsOverweight
Apr 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings


Related Articles (HTWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters